Advertisement
U.S. Markets closed

The Greater Cannabis Company, Inc. (GCAN)

OTC Markets OTCPK - OTC Markets OTCPK Delayed Price. Currency in USD
0.00050.0000 (0.00%)
At close: 09:30AM EST
Full screen
Trade prices are not sourced from all markets
Previous Close0.0005
Open0.0005
Bid0.0005 x 0
Ask0.0005 x 0
Day's Range0.0005 - 0.0005
52 Week Range0.0004 - 0.0015
Volume490,100
Avg. Volume1,602,005
Market Cap402,319
Beta (5Y Monthly)1.62
PE Ratio (TTM)N/A
EPS (TTM)-0.0000
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    GCANRx Announces Completion of Preclinical Study for Neuropsychiatric Cannabinoid Therapy

    BALTIMORE, MD, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTC: GCAN) a biopharmaceutical company pioneering development of next generation cannabinoid therapeutics and consumer products today announced that it has completed the preclinical phase of assessing its novel neuropsychiatric cannabinoid therapy. The Company had previously announced the preclinical study as part of its license and research agreement with Shaare Zedek Scientific related